Protein Blends (Soy, Whey and Casein) for Muscle Synthesis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01358305 |
Recruitment Status :
Completed
First Posted : May 23, 2011
Last Update Posted : October 7, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Muscle Synthesis | Other: Protein Blend | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 19 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Basic Science |
Official Title: | A Randomized, Controlled Double Blind Acute Study: Effects of Protein Blends on Muscle Protein Synthesis and Breakdown |
Study Start Date : | January 2011 |
Actual Primary Completion Date : | August 2012 |
Actual Study Completion Date : | March 2013 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Whey Protein Isolate |
Other: Protein Blend
Single intake of approximately 20 grams of total protein |
Experimental: Protein Blend (soy, whey and casein) |
Other: Protein Blend
Single intake of approximately 20 grams of total protein |
- Muscle Protein Synthesis or Fractional synthesis rate (FSR) [ Time Frame: baseline, 3 hours, 5 hours ]The fractional synthesis rate (FSR) of mixed muscle proteins will be calculated from the incorporation rate of L-[ring-13C6]Phenylalanine into the mixed muscle proteins, and the free-tissue phenylalanine enrichment.
- oxidative and inflammatory markers [ Time Frame: baseline, 3 hours, 5 hours ]Proteins will be assessed that are markers of oxidative damage and inflammation (NFkB, IL-1, IL-6) and proteolysis (MuRF, MAFBx).
- Phosphorylation of protein in muscle protein signaling pathways [ Time Frame: baseline, 3 hours, 5 hours ]Phosphorylation of mTOR, 4E-BP1, S6K1, S6, and eEF2 will be measured using Western blot techniques as previously described.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion:
- Age 18-35 yrs
- Stable body weight for at least 1 year
Exclusion criteria will be:
- Exercise training (>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)
- Significant heart, liver, kidney, blood, or respiratory disease
- Peripheral vascular disease
- Diabetes mellitus or other untreated endocrine disease
- Active cancer (all groups) and history of cancer (groups potentially randomizable to rapamycin)
- Acute infectious disease or history of chronic infections (e.g. TB, hepatitis, HIV, herpes)
- Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.
- Alcohol or drug abuse
- Tobacco use (smoking or chewing)
- Malnutrition (BMI < 20 kg/m2, hypoalbuminemia, and/or hypotransferrinemia)
- Obesity (BMI > 30 kg/m2)
- Low hemoglobin levels (below normal values)
- Food allergies
- Taking dietary supplements such as green tea, etc.
- Currently on a high-soy diet (consuming >2 servings of soy per day)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01358305
United States, Texas | |
UTMB General Clinical Research Center, located in the John Sealy Hospital | |
Galveston, Texas, United States, 77555 |
Principal Investigator: | Ratna Mukherjea, PhD | Solae, LLC | |
Principal Investigator: | Mark B Cope, PhD | Solae, LLC | |
Principal Investigator: | Blake B Rasmussen, PhD | UTMB |
Responsible Party: | DuPont Nutrition and Health |
ClinicalTrials.gov Identifier: | NCT01358305 |
Other Study ID Numbers: |
CRC-D-176 |
First Posted: | May 23, 2011 Key Record Dates |
Last Update Posted: | October 7, 2019 |
Last Verified: | October 2019 |
muscle synthesis mTOR antioxidant |
inflammatory markers soy protein whey casein |